2. Membrane Transporter/Ion Channel
  3. Na+/K+ ATPase
  4. Bufalin

Bufalin is an active component isolated from Chan Su, acts as a potent Na+/K+-ATPase inhibitor, binds to the subunit α1, α2 and α3, with Kd of 42.5, 45 and 40 nM, respectively. Anti-cancer activity.

For research use only. We do not sell to patients.

CAS No. : 465-21-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Bufalin:

Bufalin Related Antibodies

Top Publications Citing Use of Products

    Bufalin purchased from MedChemExpress. Usage Cited in: Apoptosis. 2023 Oct;28(9-10):1390-1405.  [Abstract]

    Bufalin (12.5, 25, 50, 100, 200 nM; 24, 48, 72 h) significantly reduces the viability of MKN-45 and HGC-27 GC cells in a dose- and time-dependent manner.

    Bufalin purchased from MedChemExpress. Usage Cited in: Apoptosis. 2023 Oct;28(9-10):1390-1405.  [Abstract]

    Bufalin (20-80 nM; 12-24 h) significantly inhibited the migration ability of MKN-45 and HGC-27 GC cell lines in a dose-dependent manner.

    Bufalin purchased from MedChemExpress. Usage Cited in: Apoptosis. 2023 Oct;28(9-10):1390-1405.  [Abstract]

    Bufalin (1 mg/kg; 100 μL; i.p.; every two days for 2–3 weeks) significantly decreased the tumor volume of gastric cancer (GC) xenograft mice.

    Bufalin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2021 Dec:174:105927.  [Abstract]

    CCK8 assay of HCT116 cells upon Bufalin (BFL) (0-0.3 μM; 24 h) treatment at indicated doses.

    Bufalin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2021 Dec:174:105927.  [Abstract]

    Bufalin (BFL) (0.03-0.3 μM; 24 h) caused TOP3β depletion in HCT116 cells.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Bufalin is an active component isolated from Chan Su, acts as a potent Na+/K+-ATPase inhibitor, binds to the subunit α1, α2 and α3, with Kd of 42.5, 45 and 40 nM, respectively[1][2]. Anti-cancer activity[2].

    IC50 & Target

    Kd: 42.5 nM (Na,K-ATPase α1), 45 nM (Na,K-ATPase α2), 40 nM (Na,K-ATPase α3)[1]
    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    0.6 3
    Compound: 7
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    786-0 EC50
    7.5 1
    Compound: 4
    Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    786-0 EC50
    7.5 1
    Compound: 4
    Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    A549 IC50
    0.6 3
    Compound: 7
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    A549 IC50
    0.6 3
    Compound: 7
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    Bel-7402 IC50
    7*10-3 75
    Compound: 1
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    BGC-823 IC50
    0.99 81
    Compound: 6, bufalin
    Cytotoxicity against human BGC823 cells
    Cytotoxicity against human BGC823 cells
    		[PMID: 17911017]
    BGC-823 IC50
    0.99 3
    Compound: 6, bufalin
    Cytotoxicity against human BGC823 cells
    Cytotoxicity against human BGC823 cells
    		[PMID: 17911017]
    Bel-7402 IC50
    7 1
    Compound: 1
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    BGC-823 IC50
    4.5*10-2 75
    Compound: 1
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    BGC-823 IC50
    4.5 x 10-2 3
    Compound: 1
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    BGC-823 IC50
    4.5 x 10-2 3
    Compound: 1
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    CCRF S-180 EC50
    >20 3
    Compound: 4
    Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    BXPC-3 EC50
    11 1
    Compound: 4
    Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    BXPC-3 EC50
    11 1
    Compound: 4
    Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    CCRF S-180 IC50
    >50 3
    Compound: 1
    Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    CCRF S-180 EC50
    > 20000 1
    Compound: 4
    Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    Bel-7402 IC50
    7 x 10-3 3
    Compound: 1
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    CCRF S-180 EC50
    > 20000 1
    Compound: 4
    Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    CCRF S-180 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    CNE IC50
    0.279 3
    Compound: 1
    Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    CCRF S-180 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    CNE IC50
    0.279 3
    Compound: 1
    Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    CNE2Z IC50
    0.46 3
    Compound: 1
    Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    H22 IC50
    >50 3
    Compound: 1
    Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    CNE2Z IC50
    0.46 3
    Compound: 1
    Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    CNE IC50
    0.279 3
    Compound: 1
    Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    786-0 EC50
    7.5 1
    Compound: 4
    Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    H22 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    SK-OV-3 EC50
    10 1
    Compound: 4
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HCT-116 EC50
    11 1
    Compound: 4
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HeLa IC50
    2.8 x 10-2 3
    Compound: 1
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    BXPC-3 EC50
    11 1
    Compound: 4
    Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HCT-116 EC50
    11 1
    Compound: 4
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HeLa IC50
    279.9 1
    Compound: Bufalin
    Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30245398]
    HeLa IC50
    594.2 1
    Compound: Bufalin
    Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 30245398]
    HUVEC EC50
    12 1
    Compound: 4
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    NCI-H1975 EC50
    13 1
    Compound: 4
    Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HepG2 IC50
    0.345 3
    Compound: 1
    Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    U-87MG ATCC EC50
    14 1
    Compound: 4
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HepG2 IC50
    0.589 3
    Compound: 1
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    HeLa IC50
    0.73 81
    Compound: 6, bufalin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 17911017]
    HepG2 IC50
    0.6 3
    Compound: 7
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    HepG2 EC50
    35 1
    Compound: 4
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HeLa IC50
    2.8*10-2 75
    Compound: 1
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    HL-60 IC50
    < 0.01 6
    Compound: 16
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    MES-SA/Dx5 EC50
    18 1
    Compound: 4
    Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HepG2 IC50
    0.345 3
    Compound: 1
    Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    HUVEC EC50
    12 1
    Compound: 4
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    KB IC50
    0.67 6
    Compound: 16
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    HepG2 IC50
    0.64 81
    Compound: 6, bufalin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 17911017]
    MCF7 EC50
    42 1
    Compound: 4
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HepG2 IC50
    0.6 3
    Compound: 7
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    HepG2 IC50
    0.589 3
    Compound: 1
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    MES-SA EC50
    28 1
    Compound: 4
    Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    CNE2Z IC50
    0.46 3
    Compound: 1
    Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    HL-60 IC50
    <0.01 6
    Compound: 16
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    MES-SA/Dx5 EC50
    18 1
    Compound: 4
    Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    H22 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    MES-SA EC50
    28 1
    Compound: 4
    Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HCT-116 EC50
    11 1
    Compound: 4
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MH60 IC50
    > 25 6
    Compound: 16
    Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    MH60 IC50
    > 64.8 3
    Compound: 3
    Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
    Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
    		[PMID: 15620253]
    HL-60 IC50
    < 0.01 6
    Compound: 16
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    HepG2 EC50
    35 1
    Compound: 4
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    KB IC50
    0.67 6
    Compound: 16
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    MH60 IC50
    31.9 3
    Compound: 3
    Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
    Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
    		[PMID: 15620253]
    HUVEC EC50
    12 1
    Compound: 4
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MCF7 EC50
    42 1
    Compound: 4
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    NCI-H1975 EC50
    13 1
    Compound: 4
    Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MH60 IC50
    >25 6
    Compound: 16
    Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    SK-OV-3 EC50
    10 1
    Compound: 4
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MH60 IC50
    31.9 3
    Compound: 3
    Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
    Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
    		[PMID: 15620253]
    U-87MG ATCC EC50
    14 1
    Compound: 4
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MH60 IC50
    >64.8 3
    Compound: 3
    Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
    Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
    		[PMID: 15620253]
    HeLa IC50
    279.9 1
    Compound: Bufalin
    Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30245398]
    HeLa IC50
    0.73 3
    Compound: 6, bufalin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 17911017]
    HeLa IC50
    594.2 1
    Compound: Bufalin
    Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 30245398]
    HeLa IC50
    2.8 x 10-2 3
    Compound: 1
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 15844967]
    HeLa IC50
    279.9 1
    Compound: Bufalin
    Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30245398]
    HeLa IC50
    594.2 1
    Compound: Bufalin
    Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 30245398]
    HepG2 EC50
    35 1
    Compound: 4
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    HepG2 IC50
    0.345 3
    Compound: 1
    Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    HepG2 IC50
    0.589 3
    Compound: 1
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23799775]
    HepG2 IC50
    0.6 3
    Compound: 7
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    HepG2 IC50
    0.64 3
    Compound: 6, bufalin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 17911017]
    KB IC50
    0.67 6
    Compound: 16
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    MCF7 EC50
    42 1
    Compound: 4
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MES-SA EC50
    28 1
    Compound: 4
    Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MESSA cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MES-SA/Dx5 EC50
    18 1
    Compound: 4
    Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human MES-SA/Dx5 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    MH60 IC50
    31.9 3
    Compound: 3
    Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
    Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
    		[PMID: 15620253]
    MH60 IC50
    > 25 6
    Compound: 16
    Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
    		[PMID: 11575946]
    MH60 IC50
    > 64.8 3
    Compound: 3
    Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
    Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
    		[PMID: 15620253]
    NCI-H1975 EC50
    13 1
    Compound: 4
    Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    SK-OV-3 EC50
    10 1
    Compound: 4
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    U-87MG ATCC EC50
    14 1
    Compound: 4
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 30369239]
    In Vitro

    Bufalin (0, 1, 2, 4 μM for 48 hours) decreases cell viability in NCI-H460 cells[2].
    Bufalin (2 μM) increases caspae-3, Endo G and GADD153 mRNA expression, but decreases the GRP78 mRNA expression[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Bufalin Related Antibodies

    Cell Viability Assay[2]

    Cell Line: NCI-H460 cells
    Concentration: 0, 1, 2, 4 μM
    Incubation Time: 48 hours
    Result: Decreased viability of NCI-H460 cells in a dose-dependent manner.
    In Vivo

    Bufalin (0.1, 0.2, or 0.4 mg/kg, i.p., daily for 14 days) shows significant anti-tumor activity in mice bearing NCI-H460 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Forty male athymic BALB/c nu/nu mice (6-8 weeks old)[2]
    Dosage: 0.1, 0.2, or 0.4 mg/kg
    Administration: I.P. every day until 14 days
    Result: Dose-dependently suppressed tumor growth.
    Molecular Weight

    386.52

    Formula

    C24H34O4
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O)C1)C)([H])[C@]2([H])CC3)(CC[C@@H]4C(C=C5)=COC5=O)[C@]34C
    Structure Classification
    Initial Source

    toad
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (258.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5872 mL 12.9359 mL 25.8719 mL
    5 mM 0.5174 mL 2.5872 mL 5.1744 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.86%

    SDS (480 KB)

    COA (253 KB) HNMR (167 KB) LCMS (112 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.5872 mL 12.9359 mL 25.8719 mL 64.6797 mL
    5 mM 0.5174 mL 2.5872 mL 5.1744 mL 12.9359 mL
    10 mM 0.2587 mL 1.2936 mL 2.5872 mL 6.4680 mL
    15 mM 0.1725 mL 0.8624 mL 1.7248 mL 4.3120 mL
    20 mM 0.1294 mL 0.6468 mL 1.2936 mL 3.2340 mL
    25 mM 0.1035 mL 0.5174 mL 1.0349 mL 2.5872 mL
    30 mM 0.0862 mL 0.4312 mL 0.8624 mL 2.1560 mL
    40 mM 0.0647 mL 0.3234 mL 0.6468 mL 1.6170 mL
    50 mM 0.0517 mL 0.2587 mL 0.5174 mL 1.2936 mL
    60 mM 0.0431 mL 0.2156 mL 0.4312 mL 1.0780 mL
    80 mM 0.0323 mL 0.1617 mL 0.3234 mL 0.8085 mL
    100 mM 0.0259 mL 0.1294 mL 0.2587 mL 0.6468 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Bufalin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Bufalin465-21-4Na+/K+ ATPaseSodium potassium pumpInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Bufalin
    Cat. No.:
    HY-N0877
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Korean - KR (480 KB) Portuguese - PT (480 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.